Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages 996-1002

  Dharmarajan, Kavita V ^a   Wexler, Leonard H ^a   Gavane, Somali ^a   Fox, Josef J ^a   Schoder, Heiko ^a   Tom, Ashlyn K ^a   Price, Alison N ^a   Meyers, Paul A ^a   Wolden, Suzanne L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Local control; Positron emission tomography; Radiation therapy; Rhabdomyosarcoma; Treatment response

Indexed keywords

CHEMOTHERAPY; ELECTRONS; PATIENT TREATMENT; POSITRONS; RADIOTHERAPY;

INTEGRAL PART; KAPLAN-MEIER METHOD; LOCAL CONTROL; LOCAL FAILURE; POSITRON EMISSION TOMOGRAPHY (PET); RHABDOMYOSARCOMA; STANDARDIZED UPTAKE VALUES; TREATMENT RESPONSE;

POSITRON EMISSION TOMOGRAPHY;

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; IRIDIUM 192; IRINOTECAN; NAVELBINE; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHILD; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; INFANT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; ROC CURVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872017960     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.077     Document Type: Article

References (18)

1. Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med 1991; 324: 461-471.
2. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 2011; 29: 1319-1325.
3. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdo-myosarcoma. J Clin Oncol 2008; 26: 406-413.
4. Volker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441.
5. Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009; 36: 23-36.
6. Friedman D, Wolden SL, Constine L. AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children's Oncology Group. Orange County: American Society of Hematology; 2010.
7. Townsend D. Basic science of PET and PET/CT. In: Valk PE, Delbeke D, Bailey DL, et al., editors. Positron Emission Tomography: Clinical Practice. 1st ed. London: Springer; 2006. p. 13-15.
8. Boellaard R. Methodological aspects of multicenter studies with quantitative PET. Methods Mol Biol 2011; 727: 335-349.
9. Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leuk Lymphoma 2009; 50: 1748-1749.
10. Rodeberg D, Stoner J, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2009; 27: 3705-3711.
11. Jingu K, Kaneta T, Nemoto K, et al. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol 2010; 15: 184-190.
12. Schinagl DA, Span PN, Oyen WJ, et al. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011; 38: 1449-1458.
13. Hawkins DS, Conrad EU 3rd, Butrynski JE, et al. [F-18]-fluorodeoxy-D- glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 2009; 115: 3519-3525.
14. Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluro-2-deoxy-D- glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristing, procarbazine and prednisone. Leuk Lymphoma 2012; 53: 64-70.
15. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011; 118: 37-43.
16. Yeung HW, Sanches A, Squire OD, et al. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 2002; 29: 61-66.
17. Baum SH, Fruhwald M, Rahbar K, et al. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdo-myosarcoma. J Nucl Med 2011; 52: 1535-1540.
18. Krasin M, Hua C, Spunt S, et al. FDG-PET prior or subsequent to radiation is a poor predictor of local outcome in patients with Group III rhabdomyosarcoma [abstract]. Int J Rad Oncol Biol Phys 2011; 81(suppl 2): S116.